{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"38","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Engraftment defined as the evidence of donor derived cells (more than 5%) by bone marrow chimerism studies in the presence of neutrophil recovery by day 28 post stem cell (SC) infusion. Engraftment date is the first day of three (3) consecutive days that the ANC exceeds 0.5 x109/L. Delayed engraftment is defined as the evidence of engraftment beyond day 28 post SC infusion achieved after the administration of therapeutic (high dose) hematopoietic growth factors.","dispersionType":"Full Range","groups":[{"description":"Busulfan starting dose of 32 mg/m\\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.","id":"OG000","title":"Busulfan + Fludarabine + Cyclophosphamide"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From engraftment to 60 days post transplant","title":"Rate of Engraftment","type":"SECONDARY","unitOfMeasure":"days"}